Clinical studies have demonstrated that Trulicity has been successful at helping people lose weight, despite the fact that Trulicity is not indicated for weight loss
2.2 Circadian disruption as a driver of metabolic liver disease Growing evidence suggests that circadian disruption is a critical risk factor for the development and progression of MASLD (7, 32)
The STEP 5 extension trial confirmed weight loss durability at 104 weeks
Objective To identify risk factors for hyperammonaemia and investigate the impact of its management on clinical outcomes
The plasma half-life of GLP-1 is short, so GLP-1 receptor agonists (RAs) have modifications in the peptide to prolong half-life.6 As these incretin hormones are degraded by dipeptidyl peptidase-4 (DPP-4), DPP-4 inhibitors can amplify their pharmacological actions.8 Both of these two incretin-based therapies improve postprandial glucose control.6,8 Among the three drug classes, the preferred second-line treatment remains unclear ( Table 1 )
J Recept Signal Transduct Res (2021) 41(4):35762
